Mouth Ulcers in Liver Transplant Recipients as an Adverse Reaction to Tacrolimus Used in Immunosuppressive Therapy: A Report of 2 Cases

BACKGROUND Organ transplant patients take immunosuppressants to prevent transplant rejection. These substances, including cyclosporine, tacrolimus (TAC), sirolimus, and mycophenolate mofetil (MMF), can cause a variety of adverse reactions such as systemic infections, neoplastic lesions, and agranulocytosis, while the oral cavity can present with aphthous ulcers, leucoplakia, glossitis, erosions and ulcers, exophytic lesions in the oral mucosa, gingival hypertrophy, and mucosal hyperplasia. The most commonly used immunosuppressant in liver transplant (LTx) recipients is tacrolimus (TAC). Improvements in surgical techniques and the use of modern immunosuppressants have increased the long-term survival of transplant recipients, but they are still at high risk of oral lesions. CASE REPORT In the 2 liver transplant recipient patients described in this article, TAC caused necrotic and ulcerative lesions in the oral mucosa. Both patients presented similar lesions. After exclusion of other etiological factors of the lesions and the modification of immunosuppressive therapy, the lesions healed in 3-4 weeks. CONCLUSIONS Tacrolimus-induced necrotic oral ulcers are a rare adverse reaction and should be considered in the differential diagnosis for organ transplant patients with mucositis who are receiving tacrolimus therapy. Lesions of this nature occurred in both patients reported. After tacrolimus was discontinued, there was complete healing of the lesions in 3-4 weeks. Therefore, modification of the immunosuppressants used should be considered once other possible etiological factors for the lesions have been excluded. The lesions should be differentiated from mucosal injuries, blistering skin diseases, autoimmune and proliferative diseases, and hematological abnormalities. The mechanism for the development of ulcer-like lesions in the oral mucosa during therapy with tacrolimus is not known.

Authors

Institutions

Publication Details

Journal
Annals of Transplantation
Published
2025-10-14
DOI
https://doi.org/10.12659/aot.950391
Citations
1
Primary Topic
Oral and gingival health research
Type
article
Field-Weighted Citation Impact
2.02
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mouth Ulcers in Liver Transplant Recipients as an Adverse Reaction to Tacrolimus Used in Immunosuppressive Therapy: A Report of 2 Cases

Izabela Minko-Chojnowska, Ewa Krasuska‐Sławińska, Natalia Jakubanis, Aleksandra Marach
1 citations
Annals of Transplantation
Oral and gingival health research
2.02
article

Mouth Ulcers in Liver Transplant Recipients as an Adverse Reaction to Tacrolimus Used in Immunosuppressive Therapy: A Report of 2 Cases

Izabela Minko-Chojnowska, Ewa Krasuska‐Sławińska, Natalia Jakubanis, Aleksandra Marach
article en
1 citations

Abstract

BACKGROUND Organ transplant patients take immunosuppressants to prevent transplant rejection. These substances, including cyclosporine, tacrolimus (TAC), sirolimus, and mycophenolate mofetil (MMF), can cause a variety of adverse reactions such as systemic infections, neoplastic lesions, and agranulocytosis, while the oral cavity can present with aphthous ulcers, leucoplakia, glossitis, erosions and ulcers, exophytic lesions in the oral mucosa, gingival hypertrophy, and mucosal hyperplasia. The most commonly used immunosuppressant in liver transplant (LTx) recipients is tacrolimus (TAC). Improvements in surgical techniques and the use of modern immunosuppressants have increased the long-term survival of transplant recipients, but they are still at high risk of oral lesions. CASE REPORT In the 2 liver transplant recipient patients described in this article, TAC caused necrotic and ulcerative lesions in the oral mucosa. Both patients presented similar lesions. After exclusion of other etiological factors of the lesions and the modification of immunosuppressive therapy, the lesions healed in 3-4 weeks. CONCLUSIONS Tacrolimus-induced necrotic oral ulcers are a rare adverse reaction and should be considered in the differential diagnosis for organ transplant patients with mucositis who are receiving tacrolimus therapy. Lesions of this nature occurred in both patients reported. After tacrolimus was discontinued, there was complete healing of the lesions in 3-4 weeks. Therefore, modification of the immunosuppressants used should be considered once other possible etiological factors for the lesions have been excluded. The lesions should be differentiated from mucosal injuries, blistering skin diseases, autoimmune and proliferative diseases, and hematological abnormalities. The mechanism for the development of ulcer-like lesions in the oral mucosa during therapy with tacrolimus is not known.

Annals of TransplantationVol. 30
Children's Memorial Health Institute (PL)
Openalex Percentile: Top 8%
Oral and gingival health research
2.02
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.